Intercept Pharmaceuticals closes $41 million equity financing

By Elaine Rigoli

Tampa, Fla., May 16 - Intercept Pharmaceuticals, Inc. announced completion of a $41 million equity financing led by Genextra SpA, with Balyasny Asset Management and Jafco Life Science Investment also participating. Riverbank Capital Securities, Inc. and Rodman & Renshaw, LLC acted as co-placement agents in the financing.

Intercept's lead compound, INT-747, is a novel, orally available farnesoid X receptor agonist that may reduce or reverse the liver damage caused by fibrosis and obstructed bile flow (cholestasis), according to a news release.

New York-based Intercept Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small molecule drugs for the treatment of chronic liver and metabolic diseases.

Issuer:	Intercept Pharmaceuticals, Inc.
Issue:	Equity financing
Amount:	$41 million
Investors:	Genextra SpA, Balyasny Asset Management, Jafco Life Science Investment
Placement agents:	Riverbank Capital Securities, Inc. and Rodman & Renshaw, LLC
Announcement date:	May 16

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.